Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion type Assertion NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_head.
- NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion wasGeneratedBy ECO_0000203 NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_provenance.
- NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion wasDerivedFrom befree-20150227 NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_provenance.
- NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion SIO_000772 24680769 NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_provenance.
- NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion evidence source_evidence_literature NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_provenance.
- NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_assertion description "[In the TCGA dataset, low vs. high miR-378 expression was associated with longer PFS in a subset of patients with recurrent ovarian cancer treated with bevacizumab (9.2 vs. 4.2months; p=0.04).]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1002593.RAa0TQCHf56jiOZUtrRzX7XHBvqstG6neh1eSdomXSgms130_provenance.